SAIL Welcomes New VP of Engineering
Please join us in welcoming Kanchana Padmanabhan as the company’s Vice President of Engineering. Padmanabhan will lead SAIL’s engineering team as it refines the strategy and implementation of its clinical data platform. She will also work closely with the business development and product teams to continue shaping and delivering the SAIL solution.
“Kanchana’s vast experience will help us deliver the best possible product for patient advocacy groups and non-profit health organizations,” said Anne Kim, CEO, SAIL. “Her background in computational biology and machine learning allows us to be more strategic with our engineering needs, both in the short-term and long-term.”
Padmanabhan is deeply experienced in productizing machine learning solutions that serve the data needs of clients. Prior to SAIL, Padmanabhan was director of machine learning at Kinaxis (after the company acquired Rubikloud), where she delivered solutions for large CPG and retail clients. She also held the role of manager of data science at Sysomos (later acquired by Meltwater Social), which involved developing ML features to analyze the 500 million daily social conversations passing through the company’s platform.
“When I met Anne for the first time, I immediately connected with what SAIL was trying to do,” Padmanabhan said. “Returning to the startup world – where there’s unmatched excitement and passion – will be energizing for me.”
Padmanabhan obtained her Ph.D in Computer Science at North Carolina State University. While at NC State, she worked under Dr. Nagiza Samatova and collaborated with Dr. P. Murali Doraiswamy of the Duke University School of Medicine on problems pertaining to biomarker discovery through computational methods for Alzheimer’s disease. The project relied on clinical, cognitive and genetic data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI).
“With SAIL, I’m excited to rejoin the conversation around machine learning and healthcare,” Padmanabhan said. “We have a real opportunity to help patient advocacy groups and non-profit health organizations enable more clinical breakthroughs.”